Sign in or create an account to add this stock to your watchlist.
About StemlineTherapeutics (NASDAQ:STML)
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311
Debt
Debt-to-Equity RatioN/A
Current Ratio5.14
Quick Ratio5.14
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$900,000.00
Price / Sales654.17
Cash FlowN/A
Price / CashN/A
Book Value$2.91 per share
Price / Book6.68
Profitability
EPS (Most Recent Fiscal Year)($2.94)
Net Income$-67,820,000.00
Net Margins-4,689.63%
Return on Equity-101.93%
Return on Assets-82.04%
Miscellaneous
Employees37
Outstanding Shares30,270,000
StemlineTherapeutics (NASDAQ:STML) Frequently Asked Questions
What is StemlineTherapeutics' stock symbol?
StemlineTherapeutics trades on the NASDAQ under the ticker symbol "STML."
How were StemlineTherapeutics' earnings last quarter?
StemlineTherapeutics Inc. (NASDAQ:STML) posted its quarterly earnings results on Friday, March, 16th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.26. StemlineTherapeutics had a negative net margin of 4,689.63% and a negative return on equity of 101.93%. View StemlineTherapeutics' Earnings History.
When is StemlineTherapeutics' next earnings date?
What price target have analysts set for STML?
3 equities research analysts have issued 12 month price objectives for StemlineTherapeutics' shares. Their forecasts range from $16.00 to $38.00. On average, they expect StemlineTherapeutics' share price to reach $27.00 in the next year. View Analyst Ratings for StemlineTherapeutics.
Who are some of StemlineTherapeutics' key competitors?
Some companies that are related to StemlineTherapeutics include The Medicines (MDCO), Heron Therapeutics (HRTX), Acadia Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), Evotec A.G. (EVTCY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), AnaptysBio (ANAB), Puma Biotechnology (PBYI), Enanta Pharmaceuticals (ENTA), Akcea Therapeutics (AKCA) and Xencor (XNCR).
Who are StemlineTherapeutics' key executives?
StemlineTherapeutics' management team includes the folowing people:
- Dr. Ivan Bergstein, Founder, Chairman, CEO & Pres (Age 52)
- Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 58)
- Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 53)
- Dr. Eric K. Rowinsky, Consultant (Age 61)
Has StemlineTherapeutics been receiving favorable news coverage?
News articles about STML stock have trended positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. StemlineTherapeutics earned a daily sentiment score of 0.33 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 48.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are StemlineTherapeutics' major shareholders?
StemlineTherapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.20%), Lyon Street Capital LLC (4.10%), Citadel Advisors LLC (1.93%), venBio Select Advisor LLC (1.73%), Nexthera Capital LP (1.73%) and Artal Group S.A. (1.32%). Company insiders that own StemlineTherapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for StemlineTherapeutics.
Which institutional investors are selling StemlineTherapeutics stock?
STML stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, C WorldWide Group Holding A S and Trexquant Investment LP. Company insiders that have sold StemlineTherapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for StemlineTherapeutics.
Which institutional investors are buying StemlineTherapeutics stock?
STML stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, venBio Select Advisor LLC, Nexthera Capital LP, Lyon Street Capital LLC, Point72 Asset Management L.P., Artal Group S.A., BlackRock Inc. and Northern Trust Corp. View Insider Buying and Selling for StemlineTherapeutics.
How do I buy shares of StemlineTherapeutics?
Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is StemlineTherapeutics' stock price today?
One share of STML stock can currently be purchased for approximately $19.45.
How big of a company is StemlineTherapeutics?
StemlineTherapeutics has a market capitalization of $588.83 million and generates $900,000.00 in revenue each year. The biopharmaceutical company earns $-67,820,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. StemlineTherapeutics employs 37 workers across the globe.
How can I contact StemlineTherapeutics?
StemlineTherapeutics' mailing address is 750 LEXINGTON AVENUE, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]
MarketBeat Community Rating for StemlineTherapeutics (STML)
MarketBeat's community ratings are surveys of what our community members think about StemlineTherapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
StemlineTherapeutics (NASDAQ:STML) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for StemlineTherapeutics in the last 12 months. Their average twelve-month price target is $27.00, suggesting that the stock has a possible upside of 38.82%. The high price target for STML is $38.00 and the low price target for STML is $16.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.00 | $31.3333 | $33.75 | $33.40 |
| Price Target Upside: | 38.82% upside | 106.14% upside | 112.93% upside | 141.16% upside |
StemlineTherapeutics (NASDAQ:STML) Consensus Price Target History
StemlineTherapeutics (NASDAQ:STML) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
StemlineTherapeutics (NASDAQ:STML) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
StemlineTherapeutics (NASDAQ STML) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 49.78%
StemlineTherapeutics (NASDAQ STML) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/13/2018 | Kenneth Hoberman | COO | Sell | 29,987 | $17.14 | $513,977.18 | |  |
| 3/12/2018 | David Gionco | Insider | Sell | 9,183 | $17.38 | $159,600.54 | | |
| 3/12/2018 | Ivan Bergstein | CEO | Sell | 37,857 | $17.34 | $656,440.38 | | |
| 3/7/2018 | David Gionco | Insider | Sell | 1,413 | $16.56 | $23,399.28 | | |
| 3/7/2018 | Ivan Bergstein | CEO | Sell | 6,797 | $16.56 | $112,558.32 | | |
| 3/7/2018 | Kenneth Hoberman | COO | Sell | 3,027 | $16.55 | $50,096.85 | | |
| 2/27/2018 | David Gionco | Insider | Sell | 8,984 | $17.43 | $156,591.12 | | |
| 2/27/2018 | Ivan Bergstein | CEO | Sell | 24,183 | $17.42 | $421,267.86 | | |
| 2/27/2018 | Kenneth Hoberman | COO | Sell | 11,026 | $17.43 | $192,183.18 | | |
| 2/15/2018 | Ivan Bergstein | CEO | Sell | 3,820 | $15.80 | $60,356.00 | | |
| 2/15/2018 | Kenneth Hoberman | COO | Sell | 1,851 | $15.67 | $29,005.17 | | |
| 1/17/2018 | David Gionco | Insider | Sell | 4,250 | $13.43 | $57,077.50 | | |
| 1/8/2018 | Kenneth Hoberman | COO | Sell | 14,040 | $13.93 | $195,577.20 | | |
| 12/18/2017 | Kenneth Hoberman | COO | Sell | 11,983 | $14.18 | $169,918.94 | | |
| 12/15/2017 | Kenneth Hoberman | COO | Sell | 11,943 | $14.18 | $169,351.74 | | |
| 2/28/2017 | David Gionco | Insider | Sell | 6,486 | $6.99 | $45,337.14 | | |
| 2/28/2017 | Ivan Bergstein | CEO | Sell | 17,980 | $6.99 | $125,680.20 | | |
| 2/28/2017 | Kenneth Hoberman | COO | Sell | 8,027 | $6.99 | $56,108.73 | | |
| 2/27/2017 | David Gionco | CAO | Sell | 3,500 | $6.97 | $24,395.00 | | |
| 2/27/2017 | Ivan Bergstein | CEO | Sell | 7,500 | $6.97 | $52,275.00 | | |
| 2/27/2017 | Kenneth Hoberman | COO | Sell | 4,000 | $6.97 | $27,880.00 | | |
| 2/16/2017 | Ivan Bergstein | CEO | Sell | 3,652 | $6.42 | $23,445.84 | | |
| 2/16/2017 | Kenneth Hoberman | COO | Sell | 1,508 | $6.42 | $9,681.36 | | |
| 1/19/2017 | David Gionco | Insider | Sell | 3,593 | $11.46 | $41,175.78 | | |
| 1/10/2017 | Kenneth Hoberman | COO | Sell | 9,110 | $13.82 | $125,900.20 | | |
| 3/8/2016 | David Gionco | CAO | Sell | 1,148 | $5.32 | $6,107.36 | 106,467 | |
| 3/8/2016 | Ivan Bergstein | CEO | Sell | 5,537 | $5.34 | $29,567.58 | 1,846,128 | |
| 3/8/2016 | Kenneth Hoberman | COO | Sell | 2,412 | $5.34 | $12,880.08 | 297,392 | |
| 2/17/2016 | Ivan Bergstein | CEO | Sell | 3,244 | $4.46 | $14,468.24 | | |
| 2/17/2016 | Kenneth Hoberman | COO | Sell | 1,503 | $4.54 | $6,823.62 | | |
| 1/20/2016 | David Gionco | CAO | Sell | 3,217 | $4.82 | $15,505.94 | 35,244 | |
| 11/30/2015 | Ivan Bergstein | CEO | Sell | 12,235 | $8.20 | $100,327.00 | 1,926,826 | |
| 4/27/2015 | Eric K Rowinsky | Insider | Sell | 10,824 | $15.77 | $170,694.48 | | |
| 3/19/2015 | Kenneth Hoberman | COO | Sell | 17,307 | $16.43 | $284,354.01 | | |
| 1/20/2015 | David Gionco | CAO | Sell | 3,311 | $14.22 | $47,082.42 | | |
| 11/26/2014 | Ivan Bergstein | CEO | Sell | 11,974 | $14.40 | $172,425.60 | | |
| 9/3/2014 | Ivan Bergstein | CEO | Buy | 2,000 | $11.05 | $22,100.00 | | |
| 9/2/2014 | Kenneth Hoberman | COO | Buy | 2,000 | $10.99 | $21,980.00 | | |
| 9/2/2014 | Kenneth J Zuerblis | Director | Buy | 1,000 | $11.14 | $11,140.00 | | |
| 5/30/2013 | Kenneth J Zuerblis | Director | Buy | 3,000 | $16.01 | $48,030.00 | | |
(Data available from 1/1/2013 forward)
StemlineTherapeutics (NASDAQ STML) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the ...
globenewswire.com - May 18 at 9:23 AM |
 | Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress
finance.yahoo.com - May 18 at 9:23 AM |
| Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual ...
globenewswire.com - May 17 at 8:58 AM |
| Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting
finance.yahoo.com - May 17 at 8:58 AM |
 | ValuEngine Lowers StemlineTherapeutics (STML) to Hold
www.americanbankingnews.com - May 15 at 1:21 PM |
| Zacks: Analysts Anticipate StemlineTherapeutics Inc. (STML) to Announce -$0.63 EPS
www.americanbankingnews.com - May 15 at 1:20 AM |
| StemlineTherapeutics Inc. (STML) to Post Q2 2018 Earnings of ($0.60) Per Share, Wedbush Forecasts
www.americanbankingnews.com - May 14 at 1:40 AM |
 | Form 10-Q STEMLINE THERAPEUTICS For: Mar 31
www.streetinsider.com - May 11 at 9:18 AM |
| StemlineTherapeutics (STML) Posts Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 10 at 11:34 PM |
| StemlineTherapeutics (STML) Rating Reiterated by Cowen
www.americanbankingnews.com - May 10 at 9:38 PM |
| StemlineTherapeutics (STML) Given a $38.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 10 at 7:51 PM |
| Stemline Therapeutics (STML) PT Raised to $20 at Wedbush; 'Upbeat on Commercial Prospects for SL-401'
www.streetinsider.com - May 10 at 5:22 PM |
| Stemline Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:06 PM |
| Stemline Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 5:06 PM |
| StemlineTherapeutics (STML) Upgraded to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - May 8 at 2:28 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Stemline Therapeutics, Inc.
finance.yahoo.com - May 3 at 8:44 AM |
| StemlineTherapeutics (STML) Upgraded by ValuEngine to Strong-Buy
www.americanbankingnews.com - May 2 at 6:06 PM |
 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Stemline Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
www.prnewswire.com - May 1 at 2:14 PM |
| HC Wainwright Analysts Give StemlineTherapeutics (STML) a $38.00 Price Target
www.americanbankingnews.com - May 1 at 10:01 AM |
| StemlineTherapeutics (STML) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:46 AM |
| Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality ...
globenewswire.com - April 30 at 8:53 AM |
| StemlineTherapeutics Inc. (STML) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 30 at 3:34 AM |
| StemlineTherapeutics Inc. (STML) Expected to Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 27 at 1:24 PM |
 | Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting
feeds.benzinga.com - April 26 at 7:57 AM |
| Zacks Investment Research Downgrades StemlineTherapeutics (STML) to Sell
www.americanbankingnews.com - April 17 at 6:29 PM |
| Form 8-K STEMLINE THERAPEUTICS For: Apr 16
www.streetinsider.com - April 17 at 9:07 AM |
| StemlineTherapeutics (STML) Upgraded at BidaskClub
www.americanbankingnews.com - April 16 at 11:29 PM |
| Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of ...
globenewswire.com - April 16 at 4:58 PM |
 | BRIEF-Stemline Therapeutics Expands Board Of Directors With Appointment Of Darren Cline
www.reuters.com - April 16 at 8:44 AM |
| Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline
feeds.benzinga.com - April 16 at 7:46 AM |
| StemlineTherapeutics Inc. (STML) Short Interest Up 46.8% in March
www.americanbankingnews.com - April 14 at 2:29 AM |
| StemlineTherapeutics (STML) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - April 12 at 10:45 AM |
| HC Wainwright Reiterates "$34.00" Price Target for StemlineTherapeutics (STML)
www.americanbankingnews.com - April 11 at 11:52 PM |
| ValuEngine Lowers StemlineTherapeutics (STML) to Sell
www.americanbankingnews.com - April 11 at 3:58 PM |
| Zacks: Analysts Expect StemlineTherapeutics Inc. (STML) Will Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 10 at 1:22 PM |
| HC Wainwright Begins Coverage on StemlineTherapeutics (STML)
www.americanbankingnews.com - April 6 at 10:47 AM |
| Stemline Therapeutics (STML) Begins Rolling BLA Submission for SL-401
www.streetinsider.com - April 5 at 10:51 AM |
| Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401
finance.yahoo.com - April 5 at 10:51 AM |
| StemlineTherapeutics Inc. (STML) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 5 at 3:24 AM |
| StemlineTherapeutics (STML) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 12:00 AM |
| Stemline Therapeutics (STML) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 5:40 PM |
| Stemline Therapeutics (STML) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 29 at 6:54 PM |
| Stemline Therapeutics (STML) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM |
| Stemline Therapeutics (STML) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - March 23 at 8:28 PM |
 | Stemline Therapeutics Inc Stock Investors Are Betting, Not Investing
investorplace.com - March 23 at 6:33 PM |
| Stemline Therapeutics (STML) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 23 at 3:07 PM |
| Stemline Therapeutics Inc Forecasted to Earn Q1 2018 Earnings of ($0.72) Per Share (STML)
www.americanbankingnews.com - March 22 at 8:12 AM |
| Stemline Therapeutics (STML) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 21 at 10:36 PM |
| Stemline Therapeutics Inc Expected to Post FY2022 Earnings of $2.29 Per Share (STML)
www.americanbankingnews.com - March 21 at 4:40 PM |
| HC Wainwright Reiterates "$38.00" Price Target for Stemline Therapeutics (STML)
www.americanbankingnews.com - March 19 at 5:02 PM |
StemlineTherapeutics (NASDAQ:STML) SEC Filings
This page is loading this company's SEC Filings. Please wait...
StemlineTherapeutics (NASDAQ:STML) Income Statement, Balance Sheet and Cash Flow Statement
StemlineTherapeutics (NASDAQ STML) Stock Chart for Sunday, May, 20, 2018
Loading chart…
